Matcham J - Search Results

1

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. Lang AE, et al. Among authors: matcham j. Ann Neurol. 2006 Mar;59(3):459-66. doi: 10.1002/ana.20737. Ann Neurol. 2006. PMID: 16429411 Clinical Trial.

2

GDNF in Parkinson's disease: the perils of post-hoc power.

Matcham J, McDermott MP, Lang AE. Matcham J, et al. J Neurosci Methods. 2007 Jul 30;163(2):193-6. doi: 10.1016/j.jneumeth.2007.05.003. Epub 2007 May 7. J Neurosci Methods. 2007. PMID: 17540454

3

Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.

Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S. Matcham J, et al. Pharm Stat. 2011 Jan-Feb;10(1):70-3. doi: 10.1002/pst.417. Pharm Stat. 2011. PMID: 20187020

4

Making available information from studies sponsored by the pharmaceutical industry: some current practices.

O'Kelly M, Julious SA, Pyke S, Day S, Todd S, Seldrup J, Matcham J. O'Kelly M, et al. Among authors: matcham j. Pharm Stat. 2011 Jan-Feb;10(1):60-9. doi: 10.1002/pst.430. Pharm Stat. 2011. PMID: 21275036

5

The potential for bias in reporting of industry-sponsored clinical trials.

Pyke S, Julious SA, Day S, O'Kelly M, Todd S, Matcham J, Seldrup J. Pyke S, et al. Among authors: matcham j. Pharm Stat. 2011 Jan-Feb;10(1):74-9. doi: 10.1002/pst.429. Pharm Stat. 2011. PMID: 21275037

6

Missing data: discussion points from the PSI missing data expert group.

Burzykowski T, Carpenter J, Coens C, Evans D, France L, Kenward M, Lane P, Matcham J, Morgan D, Phillips A, Roger J, Sullivan B, White I, Yu LM; of the PSI Missing Data Expert Group. Burzykowski T, et al. Among authors: matcham j. Pharm Stat. 2010 Oct-Dec;9(4):288-97. doi: 10.1002/pst.391. Pharm Stat. 2010. PMID: 19844946

7

A statistician's perspective on biomarkers in drug development.

Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J; PSI Biomarker Special Interest Group. Jenkins M, et al. Among authors: matcham j. Pharm Stat. 2011 Nov-Dec;10(6):494-507. doi: 10.1002/pst.532. Epub 2011 Dec 8. Pharm Stat. 2011. PMID: 22162336 Review.

8

Decision-making in early clinical drug development.

Frewer P, Mitchell P, Watkins C, Matcham J. Frewer P, et al. Among authors: matcham j. Pharm Stat. 2016 May;15(3):255-63. doi: 10.1002/pst.1746. Epub 2016 Mar 17. Pharm Stat. 2016. PMID: 26991401

9

Integrating dose estimation into a decision-making framework for model-based drug development.

Dunyak J, Mitchell P, Hamrén B, Helmlinger G, Matcham J, Stanski D, Al-Huniti N. Dunyak J, et al. Among authors: matcham j. Pharm Stat. 2018 Mar;17(2):155-168. doi: 10.1002/pst.1841. Epub 2018 Jan 10. Pharm Stat. 2018. PMID: 29322659

10

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension.

Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK; SPIRIT-AI and CONSORT-AI Working Group. Liu X, et al. Lancet Digit Health. 2020 Oct;2(10):e537-e548. doi: 10.1016/S2589-7500(20)30218-1. Epub 2020 Sep 9. Lancet Digit Health. 2020. PMID: 33328048 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters